First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

Journal:
The Lancet Oncology
Published:
Affiliations:
8
Authors:
30
Institutions Authors Share
Peter MacCallum Cancer Centre (Peter Mac), Australia
23.000000
23.000000
23.000000
0.77
The University of Melbourne (UniMelb), Australia
7.000000
0.23